ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Arbor Biotechnologies, a genome-mining start-up that launched in 2016 and raised $15.6 million in series A funding last June, is stepping out of stealth mode with a publication detailing the discovery of a CRISPR gene-editing system—an enzyme called Cas13d—that could be used to edit RNA instead of DNA (Molecular Cell 2018, DOI: 10.1016/j.molcel.2018.02.028). The start-up will use artificial intelligence to scour genomes for useful peptides, proteins, and enzymes. Broad Institute’s Feng Zhang, one inventor of CRISPR gene editing, is among the company’s founders.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter